| ¼ò½é£º   
	²¿·ÝÖÐÎÄÑÎËáÍò¹ÅÃ¹ËØ´¦·½×ÊÁÏ£¨½ö¹©²Î¿¼£©Ó¢ÎÄÃû£ºVancomycin Hydrochloride
 ÉÌÆ·Ãû£ºVancomycin powder
 ÖÐÎÄÃû£ºÑÎËáÍò¹ÅÃ¹ËØ·Û
 Éú²úÉÌ£ºÃ÷ÖÎÖÆ»¯ÖÆÒ©
 Ò©Æ·¼ò½é
 Íò¹ÅÃ¹ËØ£¨Vancomycin ‰cËá¥Ð¥ó¥³¥Þ¥¤¥·¥óÉ¢£©ÊÇÒ»ÖÖÌÇëÄÀ࿹ÉúËØ£¬ÓÃÓÚÖÎÁÆÏ¸¾ú¸ÐȾ¡£
 ҩЧ·ÖÀàÃû³Æ
 ÌÇëÄ¿¹ÉúËØÖÆ¼Á
 Åú×¼ÈÕÆÚ£º2008Äê4ÔÂ
 É̘ËÃû
 Vancomycin
 ÐÔ×´
 ÑÎËáÍò¹ÅÃ¹ËØÎª°×É«·ÛÄ©¡£
 ¸Ã²úÆ·Ò×ÈÜÓÚË®£¬Î¢ÈÜÓÚ¼×õ£°·£¬Î¢ÈÜÓÚ¼×´¼£¬¼«Î¢ÈÜÓÚÒÒ´¼£¨95£©£¬¼¸ºõ²»ÈÜÓÚÒÒëæ¡£
 ±¾²úÆ·¾ßÓÐÎüʪÐÔ¡£
 Ò»°ãÃû
 ¥Ð¥ó¥³¥Þ¥¤¥·¥ó‰cËá‰c¡¡Vancomycin Hydrochloride
 ÂÔ¡¡ºÅ
 VCM
 »¯Ñ§Ãû
 £¨1S,2R,18R,19R,22S,25R,28R,40S£©-50-£Û3-Amino-2,3,6-trideoxy-3-C-methyl-α-L-lyxo-hexopyranosyl-£¨1→2£©-β-D-glucopyranosyloxy£Ý-22-carbamoylmethyl-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-£Û£¨2R£©-4-methyl-2-£¨methylamino£©pentanoylamino£Ý-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentaazaoctacyclo£Û26.14.2.23,6.214,17.18,12.129,33.010,25.034,39£Ýpentaconta-3,5,8,10,12£¨50£©,14,16,29,31,33£¨49£©,34,36,38,45,47-pentadecaene-40-carboxylic acid monohydrochloride
 ·Ö×Óʽ
 C66H75Cl2N9O24・HCl
 ·Ö×ÓÁ¿
 1485.71
 ˜‹Ôìʽ
 ÈÚµã
 ûÓÐÃ÷È·µÄÈ۵㡣
 £¨ÔÚ 120°C»ò¸ü¸ßʱ»áÖð½¥×ÅÉ«ºÍ·Ö½â£©
 ÉóÅúÌõ¼þ
 ¿¼Âǵ½Ê¹ÓõÄÉèÊ©¡¢ÉèÊ©µÄÌáÈ¡ÂʺÍÉèÊ©µÄÊýÁ¿£¬²ÉÈ¡ÒÔÏ´ëÊ©¡£
 1. ¼ÌÐø½øÐÐÊʵ±µÄÉÏÊкó¼à²â£¨°üÀ¨Ãô¸ÐÐÔµ÷²é£©²¢ÊÕ¼¯ÐÅÏ¢¡£
 2. ¼ÌÐøÏòÒ½ÁÆ»ú¹¹Ìṩ±ØÒªµÄÐÅÏ¢£¬ÒÔ·ÖÎöÊÕ¼¯µ½µÄÐÅÏ¢²¢È·±£ÕýȷʹÓá£
 3. ÿÄêÒ»´ÎÏòºñÉúÀͶ¯Ê¡Ìá½»»ùÓÚ¶¨ÆÚ°²È«±¨¸æµÄ±¨¸æ¡£
 ҩЧҩÀí
 ×÷ÓûúÖÆ
 1.¿¹¾ú×÷ÓÃ
 £¨1£©Íò¹ÅÃ¹ËØÔÚÌåÍâ¶ÔÆÏÌÑÇò¾ú¡¢Á´Çò¾ú¡¢·ÎÑ×Çò¾ú¡¢³¦Çò¾ú¡¢Ëó×´Ñ¿æß¸Ë¾ú£¨°üÀ¨Ëó×´Ñ¿æß¸Ë¾úºÍ¼èÄÑËó¾ú£©¡¢·ÅÏß¾úºÍÈéËá¸Ë¾ú¾ßÓп¹¾ú»îÐÔ¡£ Ëü¶Ô¸ïÀ¼ÊÏÒõÐÔ¾úûÓп¹¾ú»îÐÔ¡£
 (2)Íò¹ÅÃ¹ËØÔÚÌåÍâ¶ÔÄͼ×ÑõÎ÷ÁÖ½ð»ÆÉ«ÆÏÌÑÇò¾ú(MRSA)Óп¹¾ú»îÐÔ£¬ÓëÆäËû¿¹¾úÒ©ÎïÎÞ½»²æÄÍÒ©ÐÔ¡£´ËÍ⣬ÔÚʹÓÃMRSAµÄÌåÍâ´«´úÅàÑøÊÔÑéÖУ¬¶ÔÍò¹ÅÃ¹ËØµÄ¿¹ÐԽϵ͡£
 2.×÷ÓûúÖÆ
 Íò¹ÅÃ¹ËØµÄ×÷ÓÃÊÇÓÉÓÚÒÖÖÆÏ¸¾úϸ°û±ÚºÏ³É£¬Æä¿¹¾ú×÷ÓÃÊÇɱ¾ú×÷Óá£Ëü»¹¸Ä±äÁËϸ¾úϸ°ûĤµÄͨ͸ÐÔ¡£
 ÊÊÓ¦Ö¢
 1¡¢´«È¾ÐÔ³¦Ñ×
 <ÊÊÓþúÖÖ>
 Äͼ×ÑõÎ÷ÁÖ½ð»ÆÉ«ÆÏÌÑÇò¾ú(MRSA)¡¢¼èÄÑËó¾ú¡¢¶ÔÍò¹ÅÃ¹ËØÃô¸Ð
 <ÊÊÓ¦Ö¢>
 ¸ÐȾÐÔ³¦Ñ×£¨°üÀ¨Î±Ä¤ÐԽ᳦Ñ×£©
 2. ¹ÇËèÒÆÖ²Ê±µÄ³¦Î¸¾øÓý
 Ó÷¨ÓëÓÃÁ¿
 1.¸ÐȾÐÔ³¦Ñ×£¨°üÀ¨Î±Ä¤ÐԽ᳦Ñ×£©
 ʹÓÃʱÈܽ⣬³ÉÈ˳£ÓüÁÁ¿Îª0.125¡«0.5g£¨µÎ¶È£©¿Ú·þ£¬Ò»ÈÕ4´Î¡£
 ¿É¸ù¾Ý»¼ÕßµÄÄêÁä¡¢ÌåÖØºÍÖ¢×´µ÷Õû¼ÁÁ¿¡£
 2. ¹ÇËèÒÆÖ²Ê±µÄ³¦Î¸¾øÓý
 ʹÓÃʱÈܽ⣬һ°ã³ÉÈËÒ»´Î0.5g£¨µÎ¶È£©¿Ú·þ£¬Ò»ÈÕ4¡«6´Î£¬Óë·ÇÎüÊÕÐÔ¿¹¾ú¼Á¡¢¿¹Õæ¾ú¼ÁºÏÓá£
 ¿É¸ù¾Ý»¼ÕßµÄÄêÁä¡¢ÌåÖØºÍÖ¢×´µ÷Õû¼ÁÁ¿¡£
 °ü×°
 10Æ¿ µ¥¼Û£º2637Ôª/ÈËÃñ±Ò ¶þºÐÆð¶©
 ÖÆÔìÉ̺ͷÖÏúÉÌ
 ´óÊiÖÆÒ©Öêʽ»áÉç
 ÏúÊÛ
 Ã÷ÖÎÖÆ»¯ÖÆÒ©Öêʽ»áÉç
 ×¢£ºÒÔÉÏÖÐÎÄ´¦·½×ÊÁϲ»¹»ÍêÕû£¬Ê¹ÓÃÕßÒÔÔ´¦·½×ÊÁÏΪ׼¡£
 ÍêÕû˵Ã÷×ÊÁϸ½¼þ£º
 https://www.info.pmda.go.jp/go/pack/6113001B1143_1_01/
 |